Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.83 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.83 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12160802 | 0.92 | S1PR1 (0.71) | S1PR1S1PR3CNR1KMT2AALDH1A1 | |
| SCHEMBL12160835 | 0.92 | S1PR1 (0.71) | S1PR1S1PR3CNR1KMT2AALDH1A1 | |
| SCHEMBL12248737 | 0.92 | S1PR1 (0.80) | S1PR1S1PR3KMT2ACYP2D6CYP2C19 | |
| SCHEMBL12160812 | 0.92 | S1PR1 (0.70) | S1PR1S1PR3CNR1KMT2ACYP2D6 | |
| SCHEMBL12249452 | 0.91 | S1PR1 (0.70) | S1PR1S1PR3KMT2ACYP2D6CYP2C19 | |
| SCHEMBL12248881 | 0.91 | S1PR1 (1.00) | S1PR1S1PR3KMT2ACYP2D6CYP2C19 | |
| SCHEMBL12249308 | 0.90 | S1PR1 (0.68) | S1PR1S1PR3KMT2ACYP2D6CYP2C19 | |
| SCHEMBL12160791 | 0.90 | S1PR1 (0.71) | S1PR1S1PR3KMT2ACYP2D6CYP2C19 | |
| SCHEMBL12160864 | 0.90 | S1PR1 (0.71) | S1PR1S1PR3CNR1KMT2ACYP2D6 | |
| SCHEMBL12160795 | 0.90 | S1PR1 (0.68) | S1PR1S1PR3CNR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022225-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022225-B2 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20090131438-A1 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131438-A1 | Triazole derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131438-A1 | Triazole derivative | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR3 1/4885CNR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.